Patient Preferences in Adjuvant and Palliative Treatment of Advanced Melanoma: A Discrete Choice Experiment
Authors:
- K DiehlKDK Diehl
- M SchaarschmidtMSM Schaarschmidt
- F KiekerFKF Kieker
- B SasamaBSB Sasama
- M PronkMPM Pronk
- J OhletzJOJ Ohletz
- A KönneckeAKA Könnecke
- V MüllerVMV Müller
- J UtikalJUJ Utikal
- U HillenUHU Hillen
- W HarthWHW Harth
Open Access
- 18 March 2020
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 100 (6) , adv00083-9
Abstract
Treatment paradigms for advanced melanoma have changed fundamentally over recent years. A discrete c...Keywords
This publication has 38 references indexed in Scilit:
- Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2015
- Socioeconomic and lifestyle factors and melanoma: a systematic reviewBritish Journal of Dermatology, 2015
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- Improved Overall Survival in Melanoma with Combined Dabrafenib and TrametinibNew England Journal of Medicine, 2015
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated MelanomaNew England Journal of Medicine, 2014
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in MelanomaNew England Journal of Medicine, 2014
- Preferences for cancer treatments: an overview of methods and applications in oncologyAnnals of Oncology, 2012
- Examining the pathways linking lower socioeconomic status and advanced melanomaCancer, 2011
- Aging with multimorbidity: A systematic review of the literatureAgeing Research Reviews, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010